Quarterly report pursuant to Section 13 or 15(d)

SCHEDULE OF SEGMENT INFORMATION (Details)

v3.22.2.2
SCHEDULE OF SEGMENT INFORMATION (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Jul. 31, 2022
Jul. 31, 2021
Jul. 31, 2022
Jul. 31, 2021
Oct. 31, 2021
Segment Reporting Information [Line Items]          
Net Loss $ (2,775) $ (4,388) $ (10,242) $ (9,057)  
Total operating costs and expenses 2,797 4,388 10,266 9,572  
Less non-cash share-based compensation (1,438) (3,187) (5,474) (5,225)  
Operating costs and expenses excluding non-cash share based compensation 1,359 1,201 4,792 4,347  
Total assets 32,563   32,563   $ 36,257
Cart Therapeutics [Member]          
Segment Reporting Information [Line Items]          
Net Loss (965) (1,619) (3,975) (4,025)  
Operating costs and expenses excluding non-cash share based compensation 425 411 1,852 1,904  
Total assets 13,656   13,656   15,068
Cancer Vaccines [Member]          
Segment Reporting Information [Line Items]          
Net Loss (903) (1,464) (3,684) (3,033)  
Operating costs and expenses excluding non-cash share based compensation 378 349 1,598 1,185  
Total assets 7,606   7,606   13,276
Anti Viral Therapeutics [Member]          
Segment Reporting Information [Line Items]          
Net Loss (904) (1,262) (2,565) (2,053)  
Operating costs and expenses excluding non-cash share based compensation 554 418 1,328 827  
Total assets 11,169   11,169   7,368
Other [Member]          
Segment Reporting Information [Line Items]          
Net Loss (3) (43) (18) 54  
Operating costs and expenses excluding non-cash share based compensation 2 $ 23 14 $ 431  
Total assets $ 132   $ 132   $ 545